Compare Nano Dimension Ltd - ADR (NNDM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Summit Therapeutics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Summit Therapeutics Inc is far larger — about 42.1× Nano Dimension Ltd - ADR's market cap. Which is the better fit depends on your goals.
| NNDM | SMMT | |
|---|---|---|
Market Cap | $327.47M | $13.79B |
Sector | Technology | Health |
52-Week High | $2.14 | $26.38 |
52-Week Low | $1.21 | $12.43 |
Enterprise Value | -$77.38M | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, amid a bearish technical signal and negative cash flow. The company reported a net loss of $293.30M on $102.44M revenue in 2025, with a negative net income margin of 135.18%. Recent news highlights board changes, cost-saving initiatives, and a planned sale of MarkForged to Stratasys, aimed at reducing cash burn.
The outlook remains challenged by persistent losses and cash burn, though strategic divestitures may improve liquidity. Key risks include execution of turnaround plans and competitive pressures. Analyst sentiment is cautious given the financial performance and ongoing corporate restructuring.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
